A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis

Amebiasis, due to the pathogenic parasite Entamoeba histolytica, is a leading cause of diarrhea globally. Largely an infection of impoverished communities in developing countries, amebiasis has emerged as an important infection among returning travelers, immigrants, and men who have sex with men res...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open forum infectious diseases Ročník 5; číslo 7; s. ofy161
Hlavní autoři: Shirley, Debbie-Ann T, Farr, Laura, Watanabe, Koji, Moonah, Shannon
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Oxford University Press 01.07.2018
Témata:
Editor's Choice
Review
colitis
HIV
MSM
diarrhea
PCR
amebiasis
burden
ISSN:2328-8957, 2328-8957
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Amebiasis, due to the pathogenic parasite Entamoeba histolytica, is a leading cause of diarrhea globally. Largely an infection of impoverished communities in developing countries, amebiasis has emerged as an important infection among returning travelers, immigrants, and men who have sex with men residing in developed countries. Severe cases can be associated with high case fatality. Polymerase chain reaction–based diagnosis is increasingly available but remains underutilized. Nitroimidazoles are currently recommended for treatment, but new drug development to treat parasitic agents is a high priority. Amebiasis should be considered before corticosteroid therapy to decrease complications. There is no effective vaccine, so prevention focuses on sanitation and access to clean water. Further understanding of parasite biology and pathogenesis will advance future targeted therapeutic and preventative strategies.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofy161